WebFeb 1, 2008 · Median survival of HCC and IHC patients was 11.7 months (95% CI, 9.2 to 21.6 months) and 15.0 months (95% CI, 6.5 to 29.0 months), respectively. Conclusion: Individualized six-fraction SBRT is a safe treatment for unresectable HCC and IHC. Publication types Clinical Trial, Phase I Research Support, Non-U.S. Gov't MeSH terms … WebJul 20, 2024 · Radiotherapy, which has evolved from conventional radiotherapy to stereotactic body radiotherapy (SBRT), intensity-modulated radiotherapy (IMRT), and particle therapy (PT), is a treatment option that can be performed in the adjuvant, neoadjuvant, and definitive setting for intrahepatic cholangiocarcinoma (IHCC) and extrahepatic …
Intrahepatic Cholangiocarcinoma Clinical Trials 2024 (Updates): …
WebNov 1, 2024 · Intrahepatic cholangiocarcinoma (IHCC) is the second most common tumor arising from the epithelium of the bile ducts within the liver (followed by hepatocellular carcinoma) and accounts for approximately 10% of primary liver cancers. ... M.G. Haddock Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced ... WebSBRT finds its origins in stereotactic radiosurgery (SRS), ... . 2024 examined 69 patients with unresectable primary HCC along with 17 and 4 patients with metastatic liver disease and intrahepatic cholangiocarcinoma (IHC), respectively. Dose fractionation schedule was 45 Gy (median) in 5 fractions. In the HCC sub-group, 2-year LC and OS were 95%. small arms factory
JAMAOncology OriginalInvestigation ...
WebOct 30, 2015 · Conclusions: SBRT is an effective and reasonably safe local therapy option for unresectable intrahepatic or hilar cholangiocarcinoma. Representative treatment plan of a Hilar Cholangiocarcinoma ... WebHepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Imaging for Diagnosis, Tumor Response to Treatment and Liver Response to Radiation. Edward C. Lo, Adam N. Rucker, Michael P. Federle. ... (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management. Tyler P. Robin, David Raben, Tracey E. Schefter. WebMay 3, 2012 · Other groups have reported results using SBRT for cholangiocarcinoma, some of which are summarized in Table Table4 4 [12-16]. The largest current series includes 27 patients with unresectable cholangiocarcinoma treated with SBRT . The dose used on all patients in this study was 45 Gy in 3 fractions, prescribed to isocenter. small arms factory enfield